Filing Flows › Comparisons › TRDA vs GOVX
Entrada Therapeutics vs GeoVax Labs: TRDA and GOVX compared
Entrada Therapeutics is the larger company: $905K of revenue in its latest quarter (Q3 2026) against $852K for GeoVax Labs (Q2 2025). GeoVax Labs is growing faster (+184% against -44% a year earlier).
Where the money goes: TRDA and GOVX
Entrada Therapeutics (TRDA) · Q3 2026
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
GeoVax Labs (GOVX) · Q2 2025
GeoVax Labs, Q2 2025: revenue $852K (+184% year over year), operating margin -635.8%, net loss $5.4M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Entrada Therapeutics (TRDA) | GeoVax Labs (GOVX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2025 |
| Revenue | $905K | $852K |
| Revenue growth, Y/Y | -44% | +184% |
| Operating margin | n/m | -635.8% |
| Net earnings | −$39.7M | −$5.4M |
| Net margin | — | -630.0% |
| Operating cash flow | −$30.0M | −$4.3M |
Questions
Which is bigger, Entrada Therapeutics or GeoVax Labs?
Entrada Therapeutics is the larger company: $905K of revenue in its latest quarter (Q3 2026) against $852K for GeoVax Labs (Q2 2025).
Is Entrada Therapeutics or GeoVax Labs growing faster?
GeoVax Labs is growing faster (+184% against -44% a year earlier).
More: Entrada Therapeutics earnings · how Entrada Therapeutics makes money · GeoVax Labs earnings · how GeoVax Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Jul 28, 2025). Fiscal quarters can end on different dates. Not investment advice.